Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

Advances in Experimental Medicine and Biology

Volumn 431, Issue , 1998, Pages 587-590

  Bergman, Andries M ^a   Pinedo, Herbert M ^a   Ruiz Van Haperen, Veronique W T ^a   Veerman, Gijsbert ^a   Kuiper, Catharina M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE KINASE; DEOXYGUANOSINE DERIVATIVE; ETOPOSIDE; EXONUCLEASE; FLUOROURACIL; FOLIC ACID; GEMCITABINE; METHOTREXATE; RALTITREXED; THYMIDYLATE SYNTHASE; TRIMETREXATE;

CANCER INHIBITION; CELL GROWTH; CONFERENCE PAPER; CROSS RESISTANCE; DNA DAMAGE; ENZYME ACTIVITY; FOLATE METABOLISM; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031808788     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5381-6_113     Document Type: Conference Paper

References (13)

1. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzeel, G.A. Poore, G.C. Todd, G.B. Grindey, Evaluation of the antitumor activity of a (2′,2′-difluoro-2′-deoxycytidine), Cancer Res., 50: 44417-44422 (1990).
2. E. Boven, H. Schipper, C.A.M. Erkelens, S.A. Hatty, H.M. Pinedo, The influence of the schedule and the dose of gemcitabine on the anti-tumour efficiacy in experimental human cancer, Br. J. Cancer, 68: 52-56 (1993).
3. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, J.P. Neijt, Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients, J. Natl. Cancer Inst., 86: 1530-1533 (1994).
4. V.W.T. Ruiz van Haperen, G. Veerman, J.B. Vermorken, G.J. Peters, 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines, Biochem. Pharmacol., 46: 762-766 (1993).
5. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, W. Plunkett, Action of 2′,2′-difluorodeoxycytidine on DNA synthesis, Cancer Res., 51: 6110-6117 (1991).
6. J.A. Endicott and V. Ling, The biochemistry of P-glycoprotein-mediated multidrug resistance, Annu. Rev. Biochem., 58: 137-171 (1989).
7. C.E. Grant, G. Valdimarsson, D.R. Hipfner, K.C. Almquist, S.P.C. Cole, R.G. Deeley, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357-361 (1994).
8. V.W.T. Ruiz van Haperen, G. Veerman, S. Eriksson, E. Boven, A.P.A. Stegman, M. Hermsen, J.B. Vermorken, H.M. Pinedo, G.J. Peters, Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780, Cancer Res., 54: 4138-4143 (1994).
9. Y.P. Keepers, P.E. Pizao, G.J. Peters, J. van Ark-Otte, B. Winograd, H.M. Pinedo, Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing, Eur. J. Cancer, 27: 897-900 (1991).
10. V.W.T. Ruiz van Haperen, G. Veerman, B.J.M. Braakhuis, J.B. Vermorken, E. Boven, A. Leyva, G.J. Peters, Deoxycytidine kinase and deoxycytidine deaminase activities in human xenografts, Eur. J. Cancer, 29A: 2132-2137 (1993).
11. G.J. Peters, A. Oosterhof, J.H. Veerkamp, Metabolism of purine nucleosides in human and ovine lymphocytes and rat thymocytes and their influence on mitogenic stimulation, Biochem. Bioph. Acta, 755: 127-136 (1983).
12. A.M. Bergman, V.W.T Ruiz van Haperen, G. Veerman, C.M. Kuiper, G.J. Peters, Synergistic interaction between cisplatin and gemcitabine in vitro, Clin. Cancer Res., 2: 521-530 (1996).
13. V.W.T. Ruiz van Haperen, G. Veerman, K. Smid, H.M. Pinedo, G.J. Peters, 2′,2′-Difluorodeoxycytidine (Gemcitabine) and 2′,2′-difluorodeoxyuridine inhibit thymidylate synthase activity in solid tumour cell lines, submitted.